JP2004075654A - Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water) - Google Patents

Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water) Download PDF

Info

Publication number
JP2004075654A
JP2004075654A JP2002266101A JP2002266101A JP2004075654A JP 2004075654 A JP2004075654 A JP 2004075654A JP 2002266101 A JP2002266101 A JP 2002266101A JP 2002266101 A JP2002266101 A JP 2002266101A JP 2004075654 A JP2004075654 A JP 2004075654A
Authority
JP
Japan
Prior art keywords
water
deuterium
super light
prostatomegaly
treating osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002266101A
Other languages
Japanese (ja)
Inventor
Tatsuo Usui
臼井　龍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INTERNATL SCIENT KK
International Scientific Co Ltd
Original Assignee
INTERNATL SCIENT KK
International Scientific Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INTERNATL SCIENT KK, International Scientific Co Ltd filed Critical INTERNATL SCIENT KK
Priority to JP2002266101A priority Critical patent/JP2004075654A/en
Publication of JP2004075654A publication Critical patent/JP2004075654A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for treating osteoporosis and prostatomegaly performed by drinking deutrium-reduced water (super light water). <P>SOLUTION: This method for treating osteoporosis and prostatomegaly by the deutrium-reduced water (super light water) which is an aqueous solution suitable for human, having water and 0.1-110 ppm deutrium content, or containing 0.1-110 ppm deutrium content as an activator together with a carrier or an assistant and having a form of a pharmaceutic product or a medicinal solution, is provided. <P>COPYRIGHT: (C)2004,JPO

Description

【０００１】
【発明の属する技術分野】
本発明は、骨粗鬆症、前立腺肥大の治療を重水素減少水（スーパーライトウォーター）を飲むことによっておこなうものである。
【０００２】
【従来の技術】
一般に患者が病気や身体の不調を感ずる時には、専門家である医者の診断を受けて対処療法を得るのが通常であるが、この場合、当人が病院や診療所に直接行って治療を受ける。
【０００３】
一方で、健康食品が多数販売されている昨今において、さまざまな健康食品を入手して体質改善をする対象者が増えている。
【０００４】
【発明が解決しようとする課題】
しかしながら現実において、従来の投薬治療や健康食品による体質改善が治療として成果が上がらないことがあった。
【０００５】
【課題を解決するための手段】
本発明者等は係る課題を解決するために鋭意研究したところ、骨粗鬆症、前立腺肥大の治療のための重水素減少水（スーパーライトウォーター）の飲用方法を開発して、本発明を提供するものである。
【０００６】
すなわち本発明は骨粗鬆症、前立腺肥大の治療に最適な重水素減少水（スーパーライトウォーター）の飲用方法を特徴とする重水素減少水（スーパーライトウォーター）の飲用方法である。
【０００７】
【発明の実施の形態】
本発明は重水素減少水（スーパーライトウォーター）を毎日２リットル飲むことにより２週間ぐらいで効果が表れる。
【０００８】
重水素減少水（スーパーライトウォーター）を飲んでいる間は、緑茶、味噌汁など通常飲食する物に関しても重水素減少水（スーパーライトウォーター）を使用する。
【０００９】
以下実施例をもって本発明を詳細に説明するが、本発明の範囲はこれに限定されるものではない。
【００１０】
【実施例１】
本発明の発明者は６０歳であり、膝の関節が外れやすく尿のでも悪かった。そのため重水素減少水（スーパーライトウォーター）を毎日２リットル飲みつづけた。
【００１１】
２週間後ぐらいから膝の状態が良くなり、次いで尿の出も良くなり１５秒以内ですべて出るようになった。[0001]
BACKGROUND OF THE INVENTION
The present invention treats osteoporosis and prostatic hypertrophy by drinking deuterium-reduced water (super light water).
[0002]
[Prior art]
In general, when a patient feels sick or unwell, it is normal to get treatment from a doctor who is a specialist. In this case, the person goes directly to a hospital or clinic for treatment. .
[0003]
On the other hand, in recent years when many health foods are sold, the number of subjects who obtain various health foods and improve their constitution is increasing.
[0004]
[Problems to be solved by the invention]
However, in reality, conventional medication and health improvement by health foods may not be successful as treatment.
[0005]
[Means for Solving the Problems]
The present inventors have intensively studied to solve such problems, and have developed a method for drinking deuterium-depleted water (super light water) for the treatment of osteoporosis and prostatic hypertrophy, and provide the present invention. is there.
[0006]
That is, the present invention is a method for drinking deuterium-reduced water (superlight water) characterized by a method for drinking deuterium-reduced water (superlight water) that is optimal for the treatment of osteoporosis and prostatic hypertrophy.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
The present invention is effective in about 2 weeks by drinking 2 liters of deuterium-reduced water (super light water) every day.
[0008]
While drinking deuterium-reduced water (super light water), deuterium-reduced water (super light water) is also used for foods that are normally eaten and consumed, such as green tea and miso soup.
[0009]
Hereinafter, the present invention will be described in detail with reference to examples, but the scope of the present invention is not limited thereto.
[0010]
[Example 1]
The inventor of the present invention was 60 years old, and the knee joint was easy to come off. Therefore, he continued to drink 2 liters of deuterium-reduced water (super light water) every day.
[0011]
About two weeks later, the condition of the knee improved, and then the urine output improved, and everything started within 15 seconds.

Claims (1)

水と、０．１〜１１０ｐｐｍの含有量の重水素を有し、又は、活性剤として、０．１〜１１０ｐｐｍの含有量の重水素を含み、担体又は助剤と共に、製薬学的な製品或いは医薬溶液の形での、ヒトに適する水性溶液である、重水素減少水（スーパーライトウォーター）による骨粗鬆症、前立腺肥大の治療方法。A pharmaceutical product or with water and a deuterium content of 0.1 to 110 ppm, or as an activator, containing a deuterium content of 0.1 to 110 ppm, together with a carrier or auxiliary agent A method for treating osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water), which is an aqueous solution suitable for humans in the form of a pharmaceutical solution.
JP2002266101A 2002-08-09 2002-08-09 Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water) Pending JP2004075654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002266101A JP2004075654A (en) 2002-08-09 2002-08-09 Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002266101A JP2004075654A (en) 2002-08-09 2002-08-09 Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water)

Publications (1)

Publication Number Publication Date
JP2004075654A true JP2004075654A (en) 2004-03-11

Family

ID=32024713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002266101A Pending JP2004075654A (en) 2002-08-09 2002-08-09 Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water)

Country Status (1)

Country Link
JP (1) JP2004075654A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120522A1 (en) * 2004-06-09 2005-12-22 Ltt Bio-Pharma Co., Ltd. Rheumatism preventive or therapeutic agent and beverage each comprising reduced-deuterium water
WO2006085785A1 (en) 2005-02-08 2006-08-17 Timantti Ab Non-alcoholic beverage enriched with 1h216o
EP2039364A2 (en) * 2006-06-19 2009-03-25 Woodford Associates Limited Means and method for enhancing a human sexual activity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120522A1 (en) * 2004-06-09 2005-12-22 Ltt Bio-Pharma Co., Ltd. Rheumatism preventive or therapeutic agent and beverage each comprising reduced-deuterium water
WO2006085785A1 (en) 2005-02-08 2006-08-17 Timantti Ab Non-alcoholic beverage enriched with 1h216o
AU2005327332B2 (en) * 2005-02-08 2010-07-22 Woodford Associates Limited Non-alcoholic beverage enriched with 1H216O
EA015511B1 (en) * 2005-02-08 2011-08-30 Тимантти Аб Non-alcoholic beverage enriched withho
EP2039364A2 (en) * 2006-06-19 2009-03-25 Woodford Associates Limited Means and method for enhancing a human sexual activity
EP2039364A4 (en) * 2006-06-19 2010-12-15 Woodford Associates Ltd Means and method for enhancing a human sexual activity

Similar Documents

Publication Publication Date Title
Kaplan et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations
Zeitlin et al. Modern approach to children with osteogenesis imperfecta
Beck Geriatrics review syllabus: a core curriculum in geriatric medicine
DE69400799D1 (en) USE OF RILUZOL FOR THE TREATMENT OF PARKINSON AND THE PARKINSON SYNDROME
CY1112184T1 (en) PYRIDOXAMINE FOR USE IN TREATMENT OF DIABETIC Nephropathy in Type II Diabetes
PT914110E (en) METHOD OF MODULATING MICRO-CIRCULATION
Silverman The Pill Book: The Illustrated Guide to the Most-prescribed Drugs in the United States
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
TR200101163T2 (en) Bile water substituted phenyl-alkenoylguanidines, production methods, uses
ATE406904T1 (en) A PHARMACEUTICAL COLLOIDAL COMPOSITION CONTAINING HYALURONIC ACID BIOPOLYMERS FOR THE TREATMENT OF RESPIRATORY DISEASES
JP2004075654A (en) Method for treating osteoporosis and prostatomegaly by deuterium-reduced water (super light water)
EP1393738A4 (en) Drugs for diabetes
DE60204694D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF HEART FAILURE
HUP0401798A2 (en) Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states
DuPont Treatment of travelers' diarrhea.
SE0102887D0 (en) New formulation
Fornaciari et al. A remarkable case of gout in the Imperial Rome: Surgery and diseases in antiquity by osteoarchaeological, paleopathological, and historical perspectives
Bellazzini et al. Bilateral anterior shoulder dislocation in a young and healthy man without obvious cause
Ackermann Medical consultation for the elderly patient with hip fracture
Adderson et al. Traumatic myositis ossificans simulating soft tissue infection
JP2004067654A (en) Method for medical treatment with water having decreased deuterium content (super-light water)
de Bono Digoxin in eurhythmic heart failure: PROVED ornot proven'?
Ji et al. Trans-scaphoid perilunate dislocation with fractured carpal bones in a child
Marshall et al. On Call Principles and Protocols: Principles and Protocols
Davies et al. Musculoskeletal Problems